Article
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel
Rating:
0.0
Views:
58
Likes:
1
Library:
1
The CVR ($BMYRT) tied to Bristol Myers Squibb's big Celgene buyout took one more step right to the brink Monday afternoon. As some analysts had fretted about, the FDA was unable to schedule an inspection of one of the manufacturing sites that was to be used for the production of
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value